There are accumulating evidences on the role of dysregulated angiogenesis in Behçet disease. By considering that encouraging results are accumulating about the role of anti–tumor necrosis factor α (TNF-α) agents in the treatment of Behçet disease and that there are evidences of a role of anti-TNF-α agents in angiogenesis inhibition, it is conceivable that antiangiogenic effects of anti-TNF-α agents may contribute to the efficacy of these therapeutic arms in Behçet disease.